Search

Your search keyword '"Porta Etessam, J."' showing total 659 results
Start Over Author "Porta Etessam, J."
659 results on '"Porta Etessam, J."'

2. Diagnóstico y tratamiento de los trastornos de la presión intracraneal: Documento de consenso del Grupo de Estudio de Cefaleas de la Sociedad Española de Neurología

Author

García-Ull, J., González-García, N., Torres-Ferrús, M., García-Azorín, D., Molina-Martínez, I.F.J., Beltrán-Blasco, I., Santos-Lasaosa, S., Latorre, G., Gago-Veiga, A.B., Láinez, J.M., Porta-Etessam, J., Nieves-Castellanos, C., Mínguez-Olaondo, A., López-Bravo, A., Quintas, S., Morollón, N., Díaz-Insa, S., Belvís, R., and Irimia, P.

Published
2024
Full Text
View/download PDF

6. Adaptation and Validation of the Spanish Version of Decisional Conflict Scale in People with Migraine in Spain

Author

Guerrero-Peral AL, Porta-Etessam J, Rodríguez-Vico J, Núñez M, Ciudad A, Díaz-Cerezo S, Garí-Peris C, Pérez-Sádaba FJ, Lizán L, and Santos-Lasaosa S

Subjects
migraine, decision-making, decisional conflict scale, psychometric properties, adaptation, spanish, Medicine (General), R5-920
Abstract

Ángel Luis Guerrero-Peral,1 Jesús Porta-Etessam,2 Jaime Rodríguez-Vico,3 Mercedes Núñez,4 Antonio Ciudad,4 Silvia Díaz-Cerezo,4 Carla Garí-Peris,5 Francisco Javier Pérez-Sádaba,5 Luis Lizán,5 Sonia Santos-Lasaosa6 1Headache Unit, Neurology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; 2Neurology Department, Hospital Clínico San Carlos, Madrid, Spain; 3Neurology Department, Fundación Jimenez Diaz, Madrid, Spain; 4Medical Department, Eli Lilly, Madrid, Spain; 5Outcomes’ 10, Castellón, Spain; 6Neurology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, SpainCorrespondence: Mercedes Núñez, Eli Lilly, Av. de la Industria, 30, Alcobendas, Madrid, 28108, Spain, Tel +34 647447827, Email nunez_mercedes@lilly.comPurpose: We aimed to validate the Spanish version of the Decisional Conflict Scale (DCS) and analyze its psychometric properties in people with migraine.Patients and Methods: The DCS validation comprised two phases. First, a translation and cross-cultural adaptation following the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Good Practices: 1-preparation, 2-independent forward translation, 3-reconciliation, 4-back-translation, 5-harmonization, 6-clinical review, and 7-content validation in a group of migraine patients. Second, the analysis of the psychometric properties. The reliability or internal consistency of the DCS scale and subscales was assessed using Cronbach’s α value. The item-subscale correlation was also evaluated. A floor and ceiling effects for DCS score was considered when at least 15% of respondents obtained DCS > 90 (ceiling) or < 10 (floor). The construct validity was studied through the correlation between the DCS subscales and by the correlation between the DCS and other questionnaires (Decision Self-Efficacy Scale [DSES] and 9-item Shared Decision-Making [SDM-Q-9]). Spearman’s coefficients were estimated for the correlations.Results: The cross-cultural adaptation was conducted on 17 patients who completed the questionnaire in a mean of 2.4 ± 1.1 minutes. Generally, more than 75% of them considered that DCS items were adequate, easy to understand, and relevant. The psychometric properties were evaluated in a sample of n=128 patients. Accordingly, the internal consistency of DCS was high, with a Cronbach’s α of 0.97 for the scale and between 0.87 to 0.96 for subscales. Also, a slight floor effect was observed, with 24.2% of patients having DCS scores < 10. The correlation between subscales exceeded Spearman’s coefficient of 0.7. Whereas the correlation between the DCS and the other questionnaires was generally moderate (Spearman’s coefficient > 0.4).Conclusion: The Spanish version (Spain) of the DCS has very acceptable psychometric properties (reliability and construct validity) and good potential for assessing decisional conflicts among migraine patients.Keywords: migraine, decision-making, decisional conflict scale, psychometric properties, adaptation, Spanish

Published
2022

16. Multidisciplinary Management of the Adverse Effects of Apremilast

Author

Daudén Tello, E., Alonso Suárez, J., Beltrán Catalán, E., Blasco Maldonado, C., Herrero Manso, M.C., Jiménez Morales, A., Marín-Jiménez, I., Martín-Arranz, M.D., García-Merino, A., Porta Etessam, J., Rodríguez-Sagrado, M.A., Rosas Gómez de Salazar, J., Trujillo Martín, E., and Salgado-Boquete, L.

Published
2021
Full Text
View/download PDF

35. OnabotulinumtoxinA injections for atypical odontalgia: an open-label study on nine patients

Author

García-Sáez R, Gutiérrez-Viedma Á, González-García N, Gómez-Mayordomo V, Porta-Etessam J, and Cuadrado ML

Subjects
Atypical odontalgia, Neuropathic pain, OnabotulinumtoxinA, Orofacial pain, Painful trigeminal neuropathy, Persistent idiopathic facial pain., Medicine (General), R5-920
Abstract

Rafael García-Sáez,1 Álvaro Gutiérrez-Viedma1,2 Nuria González-García,1 Víctor Gómez-Mayordomo,1 Jesús Porta-Etessam,1,2 María-Luz Cuadrado1,2 1Headache Unit, Department of Neurology, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain; 2Department of Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), Madrid, Spain Background: Atypical odontalgia (AO) manifests as continuous pain in the region of one or several teeth, in the absence of signs of dental pathology. Currently, there is insufficient evidence to establish treatment guidelines for AO. The aim of this study was to describe the effectiveness and safety of treatment with OnabotulinumtoxinA (OnabotA) on a series of patients with AO. Methods: Nine patients with AO (four males and five females, aged between 31 and 77 years) received injections of OnabotA in the region of pain. The dosage used in each procedure ranged between 10 and 30 U, spread between 4 and 12 injection sites along the gums (n=9), the lips (n=3), and the hard palate (n=1). The median follow-up time was 27 months (interquartile range, IQR 20–40) and the median number of injection sessions per patient was seven (IQR 4.5–9). The assessment variables included the change in the maximal intensity of pain on a 0–10 numerical rating scale (NRS), the response latency, and the duration of the effect. Results: All patients experienced a significant improvement, with ≥50% of reduction in the intensity of the maximal pain. The median of reduction of maximal pain after treatment was six points on the NRS (IQR 5–8.5). The response latency was 2–15 days and the duration of the effect was 2–6 months. No significant adverse reactions were registered. Conclusion: OnabotA may be a safe and effective option for the treatment of AO. Keywords: neuropathic pain, orofacial pain, painful trigeminal neuropathy, persistent dentoalveolar pain, persistent idiopathic facial pain, phantom tooth pain

Published
2018

42. Diagnosis and treatment of trigeminal neuralgia: consensus statement from the Spanish Society of Neurology’s Headache Study Group

Author

Latorre, G., primary, González-García, N., additional, García-Ull, J., additional, González-Oria, C., additional, Porta-Etessam, J., additional, Molina, F.J., additional, Guerrero-Peral, A.L., additional, Belvís, R., additional, Rodríguez, R., additional, Bescós, A., additional, Irimia, P., additional, and Santos-Lasaosa, S., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results